The growing strength of China’s drug pipelines has gone hand-in-hand with a steep uptick in big pharma licensing deals.

FDA consumer safety officer discussed the challenges of navigating policy and politics in rare diseases at a recent meeting.

An upcoming decision on a rare disease drug from Biohaven Pharmaceuticals should shed light on regulatory flexibility under ...

AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Medications that prevent HIV, shrink tumors and treat seizures were invented with government funding. At research ...

AstraZeneca abandoned a rare disease drug, but a co-inventor believes the company made a formula error in analyzing clinical ...

Funded entirely by taxpayer dollars, this first-of-its-kind drug targets cellular metabolism to promote tissue repair of multiple organs.

They've identified which grants wouldn't have been funded had similar cuts been made earlier in this century and tracked the impact that likely had on drug patents. Their conclusion: Development of ...

Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

This is the October 2025 membership meeting of the Forum on Drug Discovery, Development, and Translation. Building Community Practices into a National Clinical Trials Network - A Workshop ...